Lance Armstrong and Endurance: A Clinical Interpretation of EPO, Testosterone, and Performance

What Lance Armstrong Actually Admitted to Using

Armstrong publicly confirmed PED use in a January 17, 2013 interview with Oprah Winfrey. He stated clearly: "EPO, testosterone, and human growth hormone." He also acknowledged cortisone use and described a "program" that was systematic, not opportunistic.

The 202-page USADA Reasoned Decision, published October 10, 2012, drew on sworn testimony from 26 people, including 15 riders with direct knowledge of the U.S. Postal Service team program. That document remains the most detailed public record of the alleged substances, timing, and methods of administration.

What the USADA Record States

The USADA report described micro-dosing of EPO in amounts small enough to clear standard urine tests, transfusions of autologous blood (the athlete's own stored blood), and testosterone delivered via patches or oil-based injection. Testosterone was reportedly applied topically in small quantities to maintain normal physiological ranges while still gaining recovery benefit.

Cortisone was alleged to have been used under backdated Therapeutic Use Exemptions (TUEs), a practice the report described in detail with supporting documentation.

What Armstrong Has Said Since 2013

In subsequent podcasts, including multiple episodes of his own "THEMOVE" podcast (2017, present) and a 2020 interview with journalist Kara Swisher, Armstrong has been consistent: he does not believe he could have won seven Tours without doping, and he maintains that the entire peloton operated under similar protocols at that time. These are his own public statements and should be read as first-person admissions, not clinical data.

EPO (Erythropoietin): The Compound at the Center

Erythropoietin is an endogenous glycoprotein hormone produced primarily by peritubular fibroblasts in the renal cortex. It binds the erythropoietin receptor (EPOR) on erythroid progenitor cells in bone marrow, driving differentiation and proliferation of red blood cells. Higher circulating red blood cell mass raises oxygen-carrying capacity, directly improving VO2 max and endurance performance. Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2011

Therapeutic Uses of Recombinant EPO

Recombinant human EPO (epoetin alfa, marketed as Epogen and Procrit) received FDA approval for anemia associated with chronic kidney disease, chemotherapy, and HIV therapy. FDA prescribing information for epoetin alfa The approved therapeutic dose for CKD-related anemia is 50 to 300 IU/kg administered subcutaneously or intravenously three times per week, titrated to maintain hemoglobin between 10 to 12 g/dL.

Those doses are designed to correct a deficit. They are not designed to push hemoglobin above normal ranges.

What Doping Doses Look Like

In cycling, EPO micro-dosing protocols described in peer-reviewed doping literature and corroborated by athlete testimony typically range from 20 to 50 IU/kg administered subcutaneously every two to three days during training blocks. A 2007 study published in the Journal of Applied Physiology (Parisotto et al.) and subsequent work by the World Anti-Doping Agency demonstrated that even doses as low as 20 IU/kg three times per week for four weeks raised hemoglobin by approximately 0.8 to 1.2 g/dL and improved 4 km time-trial performance by 1 to 3% in trained cyclists. Heuberger JAAC et al. Erythropoietin doping in cycling. Br J Clin Pharmacol. 2013

A 1% to 3% improvement in a Grand Tour context, spread over 21 stages, is not a small effect. It compounds.

Hematocrit Caps and Detection

The UCI (Union Cycliste Internationale) introduced a 50% hematocrit cap in 1997, framed as a "health rule" rather than an anti-doping rule, precisely because EPO itself was undetectable in urine at the time. A direct urine test for EPO was not validated and implemented until the 2000 Sydney Olympics, developed by French researcher Françoise Lasne. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature. 2000

Armstrong's Tour de France wins span 1999 to 2005. The detection window for EPO via urine immunoelectrophoresis is approximately 72 to 96 hours post-injection for standard doses. Micro-dosing shrinks that window further.

Testosterone: Recovery, Not Just Performance

Testosterone's role in the Armstrong program was described in USADA testimony as primarily restorative. Extended stage racing depletes endogenous testosterone significantly. A three-week Grand Tour generates cumulative physiological stress that drives cortisol elevation and testosterone suppression, a pattern well-documented in exercise endocrinology literature. Hoogeveen AR, Zonderland ML. Relationships between testosterone, cortisol and performance. Int J Sports Med. 1996

Exogenous Testosterone in Doping Contexts

The testosterone-to-epitestosterone (T/E) ratio was the primary detection method during the Armstrong era. A T/E ratio above 6:1 triggered a positive finding under WADA rules. Exogenous testosterone administration raises serum testosterone acutely, pushing that ratio upward. To circumvent this, the USADA report alleged micro-dosing via transdermal patches delivering testosterone in amounts small enough to keep T/E within reportable limits while still providing pharmacological benefit.

Testosterone cypionate and enanthate (the depot ester forms used clinically in TRT) have half-lives of approximately 8 days and 4.5 days, respectively. Testosterone pharmacokinetics: Testosterone Cypionate prescribing information. FDA Transdermal testosterone reaches steady state more rapidly but produces lower peak concentrations, making it better suited to a doping protocol designed to evade ratio-based testing.

Clinical TRT Parallels

In modern hormone therapy, testosterone replacement for hypogonadal men targets a total testosterone of 400 to 700 ng/dL, per the American Urological Association guidelines and the Endocrine Society's 2018 clinical practice guideline. Bhasin S et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018 Standard weekly doses of testosterone cypionate run 100 to 200 mg IM or subcutaneous, depending on the individual's metabolism and target level. That is a therapeutic range calibrated to restore normal physiology.

Armstrong's alleged use was calibrated differently: small, frequent applications timed to training blocks and testing schedules, not to physiological targets. The clinical pharmacology is the same. The intent and dose architecture were not.

Human Growth Hormone: The Recovery Accelerator

HGH (somatropin) was among the substances Armstrong confirmed using. Growth hormone stimulates IGF-1 production in the liver and peripheral tissues, promoting protein synthesis, lipolysis, and tissue repair. Devesa J et al. The complex world of growth hormone. Int J Mol Sci. 2016

Why Endurance Athletes Use HGH

In a Grand Tour, muscle microtrauma accumulates daily. HGH's anabolic and lipolytic properties make it attractive as a recovery agent: faster repair of damaged muscle fiber, preferential fuel mobilization from fat, and connective tissue support. A 2010 systematic review in Annals of Internal Medicine found that HGH administration did improve lean body mass and reduced fat mass in doping doses, but showed no statistically significant improvement in exercise capacity or strength in trained athletes. Liu H et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008 The authors noted: "Claims that growth hormone enhances physical performance are not supported by the scientific literature."

That finding does not mean athletes stopped using it. Recovery speed between stages, not peak power output, is the perceived benefit.

Detection of HGH Doping

Two approved detection methods exist: the isoform differential immunoassay (detecting recombinant vs. Pituitary-derived GH) and the biomarker method (measuring IGF-1 and P-III-NP). Holt RI et al. The detection of growth hormone abuse in sport. Growth Horm IGF Res. 2009 The isoform test has a detection window of roughly 24 to 36 hours. The biomarker test extends detection to approximately 14 days. Both were unavailable at Tour de France competitions during Armstrong's peak competitive years.

Cortisone and Corticosteroids: The Legal-Adjacent Grey Zone

Corticosteroids were listed in USADA testimony as another component of the program. Armstrong's team allegedly obtained backdated Therapeutic Use Exemptions (TUEs) for saddle-sore treatment, a practice the USADA report characterized as fraudulent.

Corticosteroids at pharmacological doses suppress the hypothalamic-pituitary-adrenal axis, reduce perceived exertion, mobilize glucose from glycogen stores, and produce a short-term sense of increased energy. Barnes PJ. Corticosteroids: the drugs and the mechanisms. Thorax. 1995 Clinically, short-course oral or intramuscular corticosteroids (e.g., 40 mg methylprednisolone IM) are used for acute inflammatory conditions, not for performance enhancement. Their ergogenic effect is dose-dependent and most pronounced under conditions of physiological exhaustion, exactly the conditions of a three-week stage race.

WADA continues to permit corticosteroid use by TUE for legitimate medical indications. The rules require advance approval and a verified diagnosis. Backdated TUEs violate those rules regardless of the medical validity of the underlying condition.

Blood Transfusions: EPO's Predecessor and Companion

The USADA record included testimony about autologous blood transfusions, a method predating recombinant EPO in the doping toolkit. Blood is drawn during base training, stored, and re-infused before competition. The transfused red blood cells raise hematocrit above the athlete's natural ceiling, with no exogenous drug to detect.

Physiology of Blood Doping

A single unit of packed red blood cells (approximately 200 to 250 mL) raises hemoglobin by roughly 1 g/dL and hematocrit by 2 to 3 percentage points. The performance effect of a 1 g/dL hemoglobin increase is estimated at 1 to 2% improvement in VO2 max. Calbet JA et al. Determinants of maximal oxygen uptake in severe acute hypoxia. Am J Physiol Regul Integr Comp Physiol. 2003

Two units, properly timed before a key mountain stage, may produce a 2 to 4% improvement in aerobic capacity. At elite Tour de France margins, that is not a minor edge.

Detection Limitations

No drug test can detect autologous blood transfusions directly. The Athlete Biological Passport, introduced by WADA in 2008 and adopted by the UCI in the same year, monitors longitudinal hematological parameters to flag statistically anomalous patterns. Sottas PE et al. The Athlete Biological Passport. Clin Chem. 2011 This approach identifies suspicious trends rather than detecting a specific substance. It was not in place during Armstrong's Tour victories.

The Athlete Biological Passport: What Changed After Armstrong

The Athlete Biological Passport (ABP) is now the primary hematological surveillance tool in elite cycling. It tracks hemoglobin, hematocrit, reticulocyte percentage, and derived parameters over time, building a personalized reference range. Deviations from an individual athlete's baseline trigger investigation rather than a simple threshold comparison.

A 2013 analysis in the British Journal of Sports Medicine found the ABP approach was 90% sensitive for detecting EPO use when micro-dosing protocols were employed, compared with approximately 40% sensitivity for direct urine EPO testing alone. Pottgiesser T et al. The Haematological Module of the Athlete Biological Passport. J Sport Sci. 2011 This is a substantial improvement, though not complete protection against sophisticated doping.

The ABP approach also makes retrospective sanctioning possible. WADA can analyze stored samples years after competition when new testing methods become available, a process that has resulted in retrospective disqualifications from the 2000 and 2004 Olympic Games.

Modern Therapeutic Context: Where These Compounds Are Legitimate

Each substance in the Armstrong program has a legitimate medical use. Understanding that distinction matters clinically.

EPO in Oncology and Nephrology

Epoetin alfa and darbepoetin alfa remain standard-of-care for chemotherapy-induced anemia (CIA) when hemoglobin drops below 10 g/dL. The ASCO/ASH 2019 guideline recommends erythropoiesis-stimulating agents for CIA to reduce transfusion requirements, with careful monitoring to avoid hemoglobin exceeding 12 g/dL due to thromboembolic risk. Bohlius J et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline. J Clin Oncol. 2019

Testosterone in Hypogonadism

Testosterone replacement therapy is indicated for men with documented hypogonadism: two morning total testosterone measurements below 300 ng/dL plus consistent symptoms. Bhasin S et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018 Standard protocols use testosterone cypionate 100 to 200 mg weekly or biweekly, or daily transdermal gels. The goal is physiological restoration, not supraphysiological elevation.

HGH in Adult GHD

Recombinant HGH is FDA-approved for adult growth hormone deficiency, short bowel syndrome, and HIV-associated wasting. FDA prescribing information for somatropin (Genotropin) Adult GHD doses are substantially lower than those used in doping: typically 0.2 to 0.5 mg/day subcutaneous, titrated by IGF-1 level. Supraphysiological doping doses are estimated at 2 to 4 IU/day (approximately 0.67 to 1.33 mg/day), three to six times therapeutic replacement levels.

VO2 Max, Hematocrit, and the Physiology of Tour Performance

Lance Armstrong's VO2 max was tested at approximately 83 to 85 mL/kg/min during his competitive peak, a figure reported by his coaches and discussed in sports science literature. For context, the highest reliably measured VO2 max in a cyclist remains 97.5 mL/kg/min (Oskar Svendsen, 2012). Lundby C, Robach P. Performance enhancement: do we need to better understand the physiology of elite athletic performance? Scand J Med Sci Sports. 2015

Raising hematocrit from 43% to 50% (the UCI ceiling) through EPO or transfusion may increase VO2 max by 4 to 7% in a well-trained athlete. At a baseline of 83 mL/kg/min, a 5% improvement yields approximately 87 mL/kg/min. Combined with the recovery benefits of testosterone and HGH across a 21-stage race, the cumulative pharmacological effect on performance is difficult to model precisely but is likely substantial.

Whether Armstrong's natural physiology plus doping explains seven Tours, or whether without doping he might have won fewer, is a question the pharmacology cannot definitively answer. What the science can say: every compound he admitted to using has a documented, dose-dependent effect on endurance performance or recovery capacity.

What This Case Changed in Anti-Doping Science

The Armstrong case accelerated several developments in anti-doping methodology.

Retrospective testing using stored samples from the 1999 Tour was conducted in 2005 by French researchers, who found EPO signatures in 6 of Armstrong's archived samples using the Lasne urine electrophoresis method. Ressiot E et al. Retrospective analysis of urine samples from 1998 and 1999 Tour de France. Ann Endocrinol (Paris). 2007 Armstrong denied the findings, citing chain-of-custody issues, and no formal sanction resulted from that analysis.

The USADA case ultimately succeeded not on laboratory evidence but on witness testimony, financial records, and the logistical evidence described in the Reasoned Decision. That shift, from biomarker detection to systemic investigation, represents a meaningful change in how doping cases are built and prosecuted.

WADA's 2021 World Anti-Doping Code now explicitly allows for non-analytical findings based on corroborating evidence other than a positive sample. WADA World Anti-Doping Code 2021. Wada-ama.org Armstrong's case was an operational prototype for that framework.